|
10 May 2023 |
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
|
|
10 May 2023 |
Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
|
|
10 May 2023 |
Sobi to Acquire CTI BioPharma
|
|
10 May 2023 |
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome
|
|
10 May 2023 |
Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
|
|
10 May 2023 |
Anokion Announces New Clinical Data from the Phase 1 ACeD Trial Supporting KAN-101 as a Potential Disease-modifying Treatment for Celiac Disease
|
|
10 May 2023 |
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification
|
|
10 May 2023 |
Lassen Therapeutics Announces Oral Presentation of Phase I Data of LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting
|
|
10 May 2023 |
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
|
|
10 May 2023 |
Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference
|
|
10 May 2023 |
Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administered Intravenously, in Non-Small Cell Lung Cancer
|
|
10 May 2023 |
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
|
|
10 May 2023 |
Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
|
|
09 May 2023 |
Arxx Therapeutics initiates first-in-human trial of AX-202 – a monoclonal antibody under development for fibrotic diseases
|
|
09 May 2023 |
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
|
|
09 May 2023 |
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
|
|
09 May 2023 |
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
|
|
09 May 2023 |
Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
|
|
09 May 2023 |
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
|
|
09 May 2023 |
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck
|
